COVID-19 Oral Medicine Market : Latest Research Reveals Key Trends for Business Growth| Pfizer Inc., Merck & Co., Inc., Ridgeback Biotherapeutics, Strides Pharma Science Limited, Atea Pharmaceuticals, F. Hoffmann-La Roche Ltd., Emcure, Glenmark Pharmaceut

Global COVID-19 Oral Medicine Market Analysis & Forecast 2019-2028

Market Introduction

The global COVID-19 oral medicine market is expected to grow at a CAGR of around 10.5% during the forecast period of 2022-2028. The COVID-19 outbreak has caused havoc globally and affected millions of individuals. The pandemic outbreak has surged the need for the development of therapeutic solutions for treating it. COVID-19 can be treated using a range of drugs such as antivirals, monoclonal antibodies, and kinase inhibitors. The increasing investment by key players in the market serves as one of the major driving factors for the growth of the COVID-19 oral medicine market during the forecast period. For instance, in June 2022, Pfizer Inc. announced to strengthen its commitment to US manufacturing with a US$ 120 million investment at its Kalamazoo, Michigan, facility, enabling US-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir and ritonavir).
In August 2021, the World Health Organization (WHO) released a report stating that Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. In addition, medicines approved to be used in case of emergency include Eli Lilly and Company's monoclonal antibodies bamlanivimab with etesevimab; Regeneron's casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechnology s Xevudy (sotrovimab); Roche's Actemra; Celltrion's Regkirona; and convalescent plasma.

Request Sample Copy @ https://www.themarketinsights.com/request-sample/265146

Market Segmentation

The global COVID-19 oral medicines market is segmented into drug class, distribution channel, end user, and region. Based on the drug class, the market is segmented into Antiviral, Anticoagulant, Monoclonal Antibodies, Immune Modulators, and Others (Sedatives, etc.). Antivirals emerged as the most popular medicines for COVID-19 in recent times. On the basis of distribution channels, the market is divided into offline and online. Moreover, based on the end users, the market is segmented into Hospitals, Clinics, Home Settings, and Others (Academic & Research Institutes). Geographically, the market is analyzed into North America, Western Europe, Eastern Europe, Asia Pacific, Latin America, Middle East & Africa.

Check for Discount @ https://www.themarketinsights.com/check-discount/265146

Market Structure and Competition Landscape
Some of the key players in the global COVID-19 oral medicine market are
Pfizer Inc.,
Merck & Co., Inc.,
Ridgeback Biotherapeutics,
Strides Pharma Science Limited,
Atea Pharmaceuticals,
F. Hoffmann-La Roche Ltd.,
Emcure,
Glenmark Pharmaceuticals Ltd.,
BioNTech SE,
Dr. Reddy s Laboratories Ltd.,
Novartis AG,
Molecular Partners,
among others.
To maintain their market position, the key players in the COVID-19 oral medicine market focus on various growth strategies such as partnerships, collaborations, geographical expansion, product launches, etc. Some of the key developments in the COVID-19 oral medicine market include,
In March 2021, Pfizer Inc. announced the initiation of a PHASE 1 study of a new oral antiviral therapeutic agent against SARS-COV-2.
In October 2020, Atea Pharmaceuticals Inc. collaborated with Roche to jointly develop AT-527, a direct-acting antiviral (DAA), in Phase-2 clinical trials.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265146

Table of Content

Chapter One: Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
Chapter Two: Assumptions and Acronyms
Chapter Three: Executive Summary
3.1. Global Market in2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
Chapter Four: Research Methodology
Chapter Five: Analysis of COVID-19 Impact and Road Ahead
Chapter Six: Market Indicators and Background
6.1. Macro-Economic Factors
6.1.1. Global Population Overview and Forecast
6.1.2. Per Capita Income by Selected Countries
6.1.3. Healthcare Expenditure by Selected Region/Countries
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, industry players expenditures, and economic conditions, among others
6.3. Supply Chain & Value Chain Analysis
6.3.1. Raw Material Suppliers
6.3.2. COVID-19 Oral Medicine Manufacturers
6.3.3. Key End Users
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter s Five Forces Analysis
Chapter Seven: Government Laws and Industry Regulations
Chapter Eight: Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
Chapter Nine: Global COVID-19 Oral Medicine Market: Key Investment Analysis
9.1. By COVID-19 Oral Medicine Companies
9.2. By Region
9.3. M&A Activities
Robust assessment of major investments made by various industry players in the areas ranging from the application, key end users, etc.
Chapter Ten: Regional Penetration of COVID-19 Oral Medicine
10.1. North America
10.2. Latin America
10.3. Western Europe
10.4. Eastern Europe
10.5. Asia Pacific
10.6. Middle East & Africa
Chapter Eleven: Pricing Analysis
11.1. By Product Type
11.2. By Region
11.2.1. North America
11.2.2. Western Europe
11.2.3. Eastern Europe
11.2.4. Asia Pacific
11.2.5. Latin America
11.2.6. Middle East & Africa
Chapter Twelve: Parent Market Overview: Global Pharmaceutical and Healthcare Market
Chapter Thirteen: Segmental Analysis
13.1. Global COVID-19 Oral Medicine Market by Drug Class
13.1.1. Segment Overview
13.1.1.1. Antiviral
13.1.1.2. Monoclonal Antibodies
13.1.1.3. Anticoagulant
13.1.1.4. Other Drug Class (Glucocorticoid)
13.2. Global COVID-19 Oral Medicine Market by Region
13.2.1. North America
13.2.2. Latin America
13.2.3. Western Europe
13.2.4. Eastern Europe
13.2.5. Asia Pacific
13.2.6. Middle East & Africa
Chapter Fourteen: Regional Analysis
14.1. North America COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.1.1. Regional Market Overview and Key Takeaways
14.1.2. North America COVID-19 Oral Medicine Market by Drug Class
14.1.3. North America COVID-19 Oral Medicine Market by Distribution Channel
14.1.4. North America COVID-19 Oral Medicine Market by End User
14.1.5. North America COVID-19 Oral Medicine Market by Country
14.1.5.1. US
14.1.5.2. Canada
14.2. Latin America COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.2.1. Regional Market Overview and Key Takeaways
14.2.2. Latin America COVID-19 Oral Medicine Market by Drug Class
14.2.3. Latin America COVID-19 Oral Medicine Market by Distribution Channel
14.2.4. Latin America COVID-19 Oral Medicine Market by End User
14.2.5. Latin America COVID-19 Oral Medicine Market by Country
14.2.5.1. Brazil
14.2.5.2. Mexico
14.2.5.3. Rest of Latin America
14.3. Western Europe COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.3.1. Regional Market Overview and Key Takeaways
14.3.2. Western EuropeCOVID-19 Oral Medicine Market by Drug Class
14.3.3. Western EuropeCOVID-19 Oral Medicine Market by Distribution Channel
14.3.4. Western EuropeCOVID-19 Oral Medicine Market by End User
14.3.5. Western EuropeCOVID-19 Oral Medicine Market by Country
14.3.5.1. Germany
14.3.5.2. UK
14.3.5.3. France
14.3.5.4. Spain
14.3.5.5. Italy
14.3.5.6. Benelux
14.3.5.7. Nordic
14.3.5.8. Rest of Western Europe
14.4. Eastern Europe COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.4.1. Regional Market Overview and Key Takeaways
14.4.2. Eastern Europe COVID-19 Oral Medicine Market by Drug Class
14.4.3. Eastern Europe COVID-19 Oral Medicine Market by Distribution Channel
14.4.4. Eastern Europe COVID-19 Oral Medicine Market by End User
14.4.5. Eastern Europe COVID-19 Oral Medicine Market by Country
14.4.5.1. Russia
14.4.5.2. Poland
14.4.5.3. Rest of Eastern Europe
14.5. Asia Pacific COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.5.1. Regional Market Overview and Key Takeaways
14.5.2. Asia Pacific COVID-19 Oral Medicine Market by Drug Class
14.5.3. Asia Pacific COVID-19 Oral Medicine Market by Distribution Channel
14.5.4. Asia Pacific COVID-19 Oral Medicine Market by End User
14.5.5. Asia Pacific COVID-19 Oral Medicine Market by Country
14.5.5.1. China
14.5.5.2. Japan
14.5.5.3. India
14.5.5.4. South Korea
14.5.5.5. Australia
14.5.5.6. ASEAN
14.5.5.7. Rest of Asia-Pacific
14.6. Middle East & Africa COVID-19 Oral Medicine Market Analysis and Forecast2019-2028
14.6.1. Regional Market Overview and Key Takeaways
14.6.2. Middle East & Africa COVID-19 Oral Medicine Market by Drug Class
14.6.3. Middle East & Africa COVID-19 Oral Medicine Market by Distribution Channel
14.6.4. Middle East & Africa COVID-19 Oral Medicine Market by End User
14.6.5. Middle East & Africa COVID-19 Oral Medicine Market by Country
14.6.5.1. GCC
14.6.5.2. South Africa
14.6.5.3. Turkey
14.6.5.4. Rest of the Middle East & Africa
Chapter Fifteen: Competitive Landscape
15.1. Competition Dashboard
15.1.1. Global and Regional Market Share Analysis
15.1.2. Market Structure by Geography
15.2. Competitive Benchmarking
15.3. Key Strategy Analysis
15.4. Company Profiles
15.4.1. Pfizer Inc.
15.4.1.1. Company Overview
15.4.1.2. Product/Service Offerings
15.4.1.3. Key Financials
15.4.1.4. Recent Developments
15.4.2. Merck & Co. , Inc.
15.4.2.1. Company Overview
15.4.2.2. Product/Service Offerings
15.4.2.3. Financials
15.4.2.4. Recent Developments
15.4.3. Ridgeback Biotherapeutics
15.4.3.1. Company Overview
15.4.3.2. Product/Service Offerings
15.4.3.3. Financials
15.4.3.4. Recent Developments
15.4.4. Strides Pharma Science Limited
15.4.4.1. Company Overview
15.4.4.2. Product/Service Offerings
15.4.4.3. Financials
15.4.4.4. Recent Developments
15.4.5. Atea Pharmaceuticals
15.4.5.1. Company Overview
15.4.5.2. Product/Service Offerings
15.4.5.3. Financials
15.4.5.4. Recent Developments
15.4.6. F. Hoffmann-La Roche Ltd.
15.4.6.1. Company Overview
15.4.6.2. Product/Service Offerings
15.4.6.3. Financials
15.4.6.4. Recent Developments
15.4.7. Emcure
15.4.7.1. Company Overview
15.4.7.2. Product/Service Offerings
15.4.7.3. Financials
15.4.7.4. Recent Developments
15.4.8. Glenmark Pharmaceuticals Ltd.
15.4.8.1. Company Overview
15.4.8.2. Product/Service Offerings
15.4.8.3. Financials
15.4.8.4. Recent Developments
15.4.9. Dr. Reddy s Laboratories Ltd.
15.4.9.1. Company Overview
15.4.9.2. Product/Service Offerings
15.4.9.3. Financials
15.4.9.4. Recent Developments
15.4.10. Novartis AG
15.4.10.1. Company Overview
15.4.10.2. Product/Service Offerings
15.4.10.3. Financials
15.4.10.4. Recent Developments
15.4.11. Molecular Partners
15.4.11.1. Company Overview
15.4.11.2. Product/Service Offerings
15.4.11.3. Financials
15.4.11.4. Recent Developments
15.4.12. Regeneron Pharmaceuticals, Inc.
15.4.12.1. Company Overview
15.4.12.2. Product/Service Offerings
15.4.12.3. Financials
15.4.12.4. Recent Developments
A comprehensive list of COVID-19 oral medicine manufacturers will be provided along with geographical reach, employee count, revenue, product capacities, and their capabilities
Chapter Sixteen: Disclaimer

Direct Contact
Jessica Joyal
+1(213)338-8279 | +1(877)376-9989
sales@themarketinsights.com

About us.
Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.